Description | Lovastatin,aHMG-CoAreductaseinhibitor,isacholesterol-loweringdrug. |
---|---|
InVitro | Lovastatinisaninactivelactoneprodrugthatmustbechemicallyorenzymaticallyconvertedtoitsdihydroxyopen-acidforminordertoelicitinhibitoryactivity.LovastatininitshydroxyacidformisanexceptionallypotentcompetitiveinhibitorofliverHMGCoAreductase[1].Lovastatin,otherthanitsanticholesterolproperty,hasdiverseapplicationsinthefieldofosteoporosis,neuro-degeneration,rheumatoidarthritis,antifungalsandalsoisreportedtoreduceproliferationoflungcancercells,breastcancer(MCF-7),livercancer(HepG2).LovastatintreatmentsshowsignificantdosedependentcytotoxiceffectonHeLacellswithIC50valueof160μg/mL.LovastatiniseffectivetoacceleratehydroxylrADIcalscavengingactivity(54.06%)atanIC50of3601μg/mL[2]. |
InVivo | Lovastatinisaninactivelactonethatishydrolyzedinthelivertoanactivef3-hydroxyacidform.ThisprincipalmetaboliteistheinhibitoroftheenzymeHMG-CoAreductase.TheKiis1nM.Lovastatinanditsβ-hydroxyacidmetabolitearehighlyboundtohumanplasmaproteins.Lovastatincrossestheblood-brainandplacentalbarriers[3].Lovastatinproducesaprofoundreductionofapolipoprotein-B-containinglipoproteins,especiallyLDLcholesteroland,toalesserextent,plasmatriglycerides,andasmallincreaseinHDLcholesterol[4]. |
ClinicalTrial | ViewMoreCollapse |
References |
|
PreparingStockSolutions |
Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent. | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellAssay [2] | Helacellsaretreatedwithlovastatin(0,5,10,20,40,80,160,320μg/mL)for24h.Cellstreatedwithculturemediumservesasanegativecontrol.cellviABIlityismeasuredusingtheMTTbasedcolorimetricassay[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly. References |
|